VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
11366
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1364
Interactions with Platform & by Email
PARTICIPANTS
341
Unique # Participated
VALIDATIONS
153
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JULY 2020
TABLES
120
PAGES
240
EDITION
15
PRICE
USD $5600
China Has Risen Into An Economic Powerhouse.
Find Out How You Can Leverage This Opportunity!
Amid the COVID-19 crisis, the global market for Pediatric Drugs and Vaccines estimated at US$100.1 Billion in the year 2020, is projected to reach a revised size of US$148.8 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Antibiotics, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$36.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Vaccines segment is readjusted to a revised 6.8% CAGR for the next 7-year period.
The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$27.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.4 Billion by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.
In the global Allergy & Respiratory segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.1 Billion in the year 2020 will reach a projected size of US$18.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$20.1 Billion by the year 2027, while Latin America will expand at a 5.3% CAGR through the analysis period. We bring years of research experience to this 15th edition of our report. The 240-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Abbott Laboratories; Allergan Inc.; Amgen Inc.; AstraZeneca Plc; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech Inc.; GlaxoSmithKline Plc; Janssen Biologics B.V; Merck & Co. Inc.; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Shionogi Inc.; Shire Pharmaceuticals Group Plc
» Therapeutic Class (Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones, Other Therapeutic Classes)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlassâ„¢ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Pediatrics: A Highly Underserved and Undervalued Group |
| Recent Market Activity |
| Pediatric Drugs Market - An Abode of Opportunities |
| The United States: Largest Market for Pediatric Drugs and Vaccines |
| Developing Markets to Witness Faster Growth |
| Antibiotics: Largest Selling Drug Classes |
| Pediatric Vaccines Market - On High Growth Trajectory |
| Supply and Demand Dynamics of the Global Vaccine Market |
| UNICEF Addresses BCG Vaccine Supply Shortage |
| Access to Vaccines Index: Aiding Increased Access to Vaccines |
| Recent Advancements/Achievements in the Pediatric Vaccines Space |
| Global Competitor Market Shares |
| Pediatric Drugs and Vaccines Competitor Market Share Scenario Worldwide (in %): 2020 & 2029 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Abbott Laboratories (USA) |
| Allergan, Inc. (USA) |
| Amgen, Inc. (USA) |
| AstraZeneca Plc. (UK) |
| Boehringer Ingelheim GmbH (Germany) |
| Bristol-Myers Squibb Company (USA) |
| Eli Lilly and Company (USA) |
| F. Hoffmann-La Roche Ltd (Switzerland) |
| Genentech, Inc. (USA) |
| GlaxoSmithKline plc. (UK) |
| Janssen Biologics B.V. (USA) |
| Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company) |
| Merck & Co., Inc. (USA) |
| Novartis AG (Switzerland) |
| Novo Nordisk A/S (Denmark) |
| Pfizer, Inc. (USA) |
| Sanofi S.A (France) |
| Shionogi Inc. (USA) |
| Shire Pharmaceuticals Group Plc. (UK) |
| 3. MARKET TRENDS & DRIVERS |
| Pediatric Exclusivity Drives Manufacturers’ Interest |
| Pediatric Exclusitivity Granted to Branded Drugs |
| New Product Approvals and Pipeline - A Key Growth Propeller |
| Recent Pediatric Drug Approvals: 2015-2017 |
| Pediatric Drug Approvals: 2011-2014 |
| Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017) |
| Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017) |
| Potential for Pediatric Drugs Against Obesity-related Conditions |
| List of Pediatric Drugs for Congestive Heart Failure Treatment |
| Recent Findings to Help Save Children’s Lives |
| Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials |
| Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials |
| Modeling & Simulation - A Powerful Tool for Pediatric Clinical Study Sponsors |
| Pharmacometrics Approaches Gain Traction Among US and EU Researchers |
| Challenges Associated with Adoption of Pharmacometric Approach |
| Guidelines for Conducting Ethically Correct Clinical Trials |
| Pediatric Drug Market - Is Off-label Prescription Justified? |
| Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine |
| High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination |
| Vaccine Refusal by Parents - A Growing Trend in the US Market |
| Orphan Drugs for Pediatric Use Gain Popularity |
| List of FDA Approved Orphan Drugs: 2015-2016 |
| List of FDA Designated Orphan Drugs: 2015-2017 |
| Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs |
| Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections |
| Approved Pediatric Antiretroviral Drugs for HIV Treatment |
| Highly Fragmented Growth Hormone Market |
| 4. GLOBAL MARKET PERSPECTIVE |
| Pediatric Drugs and Vaccines Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Pediatric Drugs and Vaccines Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 |
| Pediatric Drugs and Vaccines Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Antibiotics (Therapeutic Class) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Antibiotics (Therapeutic Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Antibiotics (Therapeutic Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Vaccines (Therapeutic Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 |
| Vaccines (Therapeutic Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 |
| Vaccines (Therapeutic Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| Allergy & Respiratory (Therapeutic Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 |
| Allergy & Respiratory (Therapeutic Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 |
| Allergy & Respiratory (Therapeutic Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| CNS (Therapeutic Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 |
| CNS (Therapeutic Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| CNS (Therapeutic Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 |
| Hormones (Therapeutic Class) World Market by Region/Country in US$ Million: 2018 to 2025 |
| Hormones (Therapeutic Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 |
| Hormones (Therapeutic Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 |
| Other Therapeutic Classes (Therapeutic Class) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 |
| Other Therapeutic Classes (Therapeutic Class) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 |
| Other Therapeutic Classes (Therapeutic Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Pediatric Drugs and Vaccines Market Share (in %) by Company: 2020 & 2025 |
| United States Pediatric Drugs and Vaccines Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025 |
| Pediatric Drugs and Vaccines Market in the United States by Therapeutic Class: A Historic Review in US$ Million for 2009-2017 |
| United States Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Canada |
| Canadian Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025 |
| Canadian Pediatric Drugs and Vaccines Historic Market Review by Therapeutic Class in US$ Million: 2009-2017 |
| Pediatric Drugs and Vaccines Market in Canada: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025 |
| Japan |
| Japanese Market for Pediatric Drugs and Vaccines: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Market in Japan: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017 |
| Japanese Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| China |
| Chinese Pediatric Drugs and Vaccines Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Historic Market Analysis in China in US$ Million by Therapeutic Class: 2009-2017 |
| Chinese Pediatric Drugs and Vaccines Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Europe |
| Market Facts & Figures |
| European Pediatric Drugs and Vaccines Market: Competitor Market Share Scenario (in %) for 2020 & 2025 |
| European Pediatric Drugs and Vaccines Market Demand Scenario in US$ Million by Region/Country: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 |
| European Pediatric Drugs and Vaccines Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Europe in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017 |
| European Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| France |
| Pediatric Drugs and Vaccines Market in France by Therapeutic Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| French Pediatric Drugs and Vaccines Historic Market Scenario in US$ Million by Therapeutic Class: 2009-2017 |
| French Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Germany |
| Pediatric Drugs and Vaccines Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025 |
| German Pediatric Drugs and Vaccines Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017 |
| German Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Italy |
| Italian Pediatric Drugs and Vaccines Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Historic Market Analysis in Italy in US$ Million by Therapeutic Class: 2009-2017 |
| Italian Pediatric Drugs and Vaccines Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Kingdom |
| United Kingdom Market for Pediatric Drugs and Vaccines: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Market in the United Kingdom: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017 |
| United Kingdom Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Spain |
| Spanish Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025 |
| Spanish Pediatric Drugs and Vaccines Historic Market Review by Therapeutic Class in US$ Million: 2009-2017 |
| Pediatric Drugs and Vaccines Market in Spain: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025 |
| Russia |
| Russian Pediatric Drugs and Vaccines Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025 |
| Pediatric Drugs and Vaccines Market in Russia by Therapeutic Class: A Historic Review in US$ Million for 2009-2017 |
| Russian Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Rest of Europe in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017 |
| Rest of Europe Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Asia-Pacific |
| Asia-Pacific Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 |
| Asia-Pacific Pediatric Drugs and Vaccines Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 |
| Pediatric Drugs and Vaccines Market in Asia-Pacific by Therapeutic Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Asia-Pacific Pediatric Drugs and Vaccines Historic Market Scenario in US$ Million by Therapeutic Class: 2009-2017 |
| Asia-Pacific Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Australia |
| Pediatric Drugs and Vaccines Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Australian Pediatric Drugs and Vaccines Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017 |
| Australian Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| India |
| Indian Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025 |
| Indian Pediatric Drugs and Vaccines Historic Market Review by Therapeutic Class in US$ Million: 2009-2017 |
| Pediatric Drugs and Vaccines Market in India: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025 |
| South Korea |
| Pediatric Drugs and Vaccines Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025 |
| South Korean Pediatric Drugs and Vaccines Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017 |
| Pediatric Drugs and Vaccines Market Share Distribution in South Korea by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Rest of Asia-Pacific |
| Rest of Asia-Pacific Market for Pediatric Drugs and Vaccines: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017 |
| Rest of Asia-Pacific Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Latin America |
| Latin American Pediatric Drugs and Vaccines Market Trends by Region/Country in US$ Million: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 |
| Latin American Pediatric Drugs and Vaccines Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 |
| Latin American Pediatric Drugs and Vaccines Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Historic Market Analysis in Latin America in US$ Million by Therapeutic Class: 2009-2017 |
| Latin American Pediatric Drugs and Vaccines Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Argentina |
| Argentinean Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Argentina in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017 |
| Argentinean Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Brazil |
| Pediatric Drugs and Vaccines Market in Brazil by Therapeutic Class: Estimates and Projections in US$ Million for the Period 2018-2025 |
| Brazilian Pediatric Drugs and Vaccines Historic Market Scenario in US$ Million by Therapeutic Class: 2009-2017 |
| Brazilian Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Mexico |
| Pediatric Drugs and Vaccines Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Mexican Pediatric Drugs and Vaccines Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017 |
| Mexican Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Rest of Latin America |
| Rest of Latin America Pediatric Drugs and Vaccines Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025 |
| Pediatric Drugs and Vaccines Market in Rest of Latin America by Therapeutic Class: A Historic Review in US$ Million for 2009-2017 |
| Rest of Latin America Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Middle East |
| The Middle East Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 |
| Pediatric Drugs and Vaccines Market in the Middle East by Region/Country in US$ Million: 2009-2017 |
| The Middle East Pediatric Drugs and Vaccines Market Share Breakdown by Region/Country: 2009, 2019, and 2025 |
| The Middle East Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025 |
| The Middle East Pediatric Drugs and Vaccines Historic Market by Therapeutic Class in US$ Million: 2009-2017 |
| Pediatric Drugs and Vaccines Market in the Middle East: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025 |
| Iran |
| Iranian Market for Pediatric Drugs and Vaccines: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Market in Iran: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017 |
| Iranian Pediatric Drugs and Vaccines Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Israel |
| Israeli Pediatric Drugs and Vaccines Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025 |
| Pediatric Drugs and Vaccines Market in Israel in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017 |
| Israeli Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Saudi Arabia |
| Saudi Arabian Pediatric Drugs and Vaccines Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Pediatric Drugs and Vaccines Historic Market Analysis in Saudi Arabia in US$ Million by Therapeutic Class: 2009-2017 |
| Saudi Arabian Pediatric Drugs and Vaccines Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Arab Emirates |
| Pediatric Drugs and Vaccines Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025 |
| United Arab Emirates Pediatric Drugs and Vaccines Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017 |
| Pediatric Drugs and Vaccines Market Share Distribution in United Arab Emirates by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Rest of Middle East |
| Pediatric Drugs and Vaccines Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025 |
| Rest of Middle East Pediatric Drugs and Vaccines Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017 |
| Rest of Middle East Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| Africa |
| African Pediatric Drugs and Vaccines Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025 |
| Pediatric Drugs and Vaccines Market in Africa by Therapeutic Class: A Historic Review in US$ Million for 2009-2017 |
| African Pediatric Drugs and Vaccines Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 92 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com